adherent patients tend to perceive a worse disease condition. Further studies can clarify if low adherence is causally associated with less efficacy of therapy.

REFERENCES

Disclosure of Interests: None declared

SLEEP DISORDER OR DEPRESSION IN KOREAN RHEUMATOID ARTHRITIS, AND ITS ASSOCIATION WITH DISEASE ACTIVITY

Kyeong Moo Son, Seoung Hun Kang, Young Il Seo, Hyun Ah Kim, Hallym University Sacred Heart Hospital, Gyeonggi-do, Korea, Rep. of (South Korea)

Background: Rheumatoid arthritis is a chronic autoimmune disease. Psychological stress and mood disorders such as sleep disorder or depression are more frequent in patient with RA.

Objectives: The aim of this study was to evaluate the relationship between disease activities and sleep disorder or depression in Korean patients with RA.

Methods: The study enrolled 334 patients with RA who visited Hallym University Sacred Heart Hospital (South Korea). The diagnosis of insomnia and depression is based in patient questionnaire such as Pittsburg sleep quality index (PSQI) and Beck depression inventory (BDI). Insomnia was defined as PSQI≥5 and depression was defined as BDI ≥13.

Results: Patients were divided into two groups (insomnia vs no-insomnia, depression vs no-depression) and the clinical aspects were compared by Mann-Whitney U-test. Age, gender, erythrocyte sedimentation rate (ESR), 28 joint disease activity score (DAS28), DAS28-P score (the subjective components of the DAS28 relative to the total components), tender joint count (TJC) and swollen joint count (SJC), quality of life measured with health assessment questionnaire (HAQ) were analyzed.

Conclusion: Rheumatoid arthritis patient with the sleep disorder or depression is more prevalent in female RA than male RA.

REFERENCES

Disclosure of Interests: None declared

AB0360E

GENDER DIFFERENCES IN CLINICAL CHARACTERISTICS AND COMORBIDITIES AND THEIR IMPACT ON CLINICAL OUTCOME IN KOREAN PATIENTS WITH RHEUMATOID ARTHRITIS

Seunghwan Shin1, Eun Ha Kang1, Yun Jong Lee1, Yeong Wook Song2, You-Jung Ha1. 1Seoul National University Bundang Hospital, Department of Internal Medicine, Gyeonggi-do, Korea, Rep. of (South Korea); 2Seoul National University Hospital, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea).

Background: Rheumatoid arthritis (RA) is a chronic auto-immune disease that is more common to female than male. Gender-based differences in clinical features, comorbidities, and disease outcomes have been fragmentarily described. However, systematic analysis focusing on gender differences in a large RA population is scarce.

Objectives: To elucidate gender differences in clinical characteristics and comorbidities and their potential impact on clinical outcome in a large Korean cohort of patients with RA.

Methods: A total of 5,376 RA patients were included from the KORean observational study Network for Arthritis (KORONA) database. Each patient was examined at baseline and three consecutive years. RA disease activity, functional disability, and quality of life were assessed by disease activity score 28 (DAS28), health assessment questionnaire (HAQ) and EuroQol-5D (EQ-5D), respectively. The subjective health-related outcomes including visual analog scale (VAS) scores for patient’s and physician’s global health, patient’s pain, fatigue, and sleep disturbance were collected. Comorbid characteristics and comorbidities at baseline were compared according to gender. Gender impacts on clinical outcome during the four years were analyzed using generalized estimating equations (GEE) models for repeated measures. In addition, the gender effect on achieving clinical remission was analyzed using Cox-proportional hazards regression.

Results: At baseline, females (n=4,574) were younger, more erosive, and had longer disease duration than male (n=802). Females showed significantly higher scores in DAS28, HAQ, EQ-5D, and VAS for all patients’ health-related outcomes. In terms of comorbidities, the prevalence of male RA was significantly higher than that of female RA in most illnesses including interstitial lung disease, cardiovascular disease, diabetes and other pulmonary disease except for depression. In the GEE model, gender was found to significantly influence the rate of change of DAS28 (p=0.041), and also independently associated with this outcome (p<0.001) after adjusting for age, disease duration, and baseline DAS28.

Conclusion: In Korean patients with RA, most comorbidities were more prevalent in male than in female. But for RA-related health outcomes, the longitudinal change in disease activity and the rate of achieving clinical remission over time were found to be worse in female RA.

REFERENCES

Disclosure of Interests: None declared

AB0360G

DETECTABLE HBV DNA AT TREATMENT BASELINE PREDICTED HEPATITIS B VIRUS REACTIVATION IN INFLAMMATORY ARTHRITIS PATIENTS WITH NEGATIVE HEPATITIS B SURFACE ANTIGEN BUT POSITIVE ANTI-HEPATITIS B CORE ANTIGEN

Grace Chup-His Hu, Queen Elizabeth Hospital, Medicine, Kowloon, Hong Kong (SAR)

Background: Hepatitis B virus (HBV) reactivation in inflammatory arthritis (IA) patients with positive hepatitis B surface antigen (HBsAg+) is one of the treatment-related complications. The risk of reactivation in patients with negative hepatitis B surface antigen but positive anti-Hepatitis B core antibody (HBSAg+/anti-HBc−) is less well defined.

Objectives: This retrospective, single centre study aimed to study the prevalence of HBV reactivation (defined as HBV DNA becoming detectable during treatment if it was undetectable at baseline, or an increase in HBV DNA titre if detectable at baseline) among IA patients with HBSAg+/anti-HBc−, and to investigate any factors predicting reactivation.

Methods: IA patients attending the rheumatology specialist clinic in a local tertiary hospital between 1st January 2011 and 31st December 2016 were included if they had HBSAg+/anti-HBc− status. Demographic data, clinical parameters including treatments for IA and any use of antiviral prophylaxis, and laboratory results including anti-Hepatitis B surface antibody (anti-HBs) and serial HBV DNA levels were obtained. Logistic regression was used to identify factors predicting HBV reactivation.

Disclosure of Interests: None declared

Disclosure of Interests: None declared
Results: Around 1/3 (68%) of the 206 included patients included were female and the mean age was 61.7-year-old. 75% had rheumatoid arthritis and the remaining had psoriatic arthritis or peripheral spondyloarthritis. Most patients (94%, n=194) were on conventional synthetic DMARD csDMARD (25 on monotherapy and 169 on combination therapy). 35% patients (n=72) were on biologic DMARD (with or without csDMARD). As antiviral prophylaxis was not mandatory in HBsAg/anti-HBc+ patients according to local protocol, only 17 patients (8.3%) were on preemptive antiviral against HBV.

Thirteen patients (6.3%) experienced HBV reactivation during their disease course and four of them were on antiviral prophylaxis. All of these reactivations were only transient low-grade viraemia with HBV DNA level ≤ 200IU/ml. Spontaneous resolution of viraemia were observed in all these patients. None of the reactivation resulted in acute hepatitis, hepatic failure or mortality.

Presence of detectable HBV DNA at baseline predicted HBV reactivation (OR 21.0, p<0.005). Other parameters including age, the lack of antiviral prophylaxis, negative anti-HBs status and anti-HBs titre were not significant predictors of HBV reactivation. None of the synthetic and biologic DMARDs were associated with HBV reactivation.

Conclusion: HBV reactivation was infrequent among IA patients with HBsAg/anti-HBc+ status and was unlikely to be associated with adverse clinical outcome. It could occur in patients with positive anti-HBs or on antiviral prophylaxis. Detectable HBV DNA at baseline was a predictor of HBV reactivation.

REFERENCES

Disclosure of Interests: None declared

Rheumatoid arthritis – biological DMARDs

AB0361
ASCORE, A 2-YEAR, OBSERVATIONAL, PROSPECTIVE MULTICENTRE STUDY OF SUBCUTANEOUS ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE: 1-YEAR INTERIM ANALYSIS

Rieke Allen1, Xavier Mariette2, Maya Buch3, Roberto Caporali4, Rene-Marc Filipo5, Adrian Forster6, Michael Nurmmohamed7, Yusuf Patel8, Peter Peichl9, Rainmon Sammann8, Melanie Chartier10, Julia Heitmann11, Christiane Rauch12, Sean Connolly13, 1University Medicine Berlin, Berlin, Germany; 2University Paris-Sud, Paris, France; 3University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom; 4University of Pavia and IRCCS S. Matteo Foundation, Pavia, Italy; 5Centre Hospitalier Universitaire de Fribourg, Fribourg, Switzerland; 6ARC Amsterdam University Hospitals – VU University Medical and Reade, Amsterdam, Netherlands; 7Hull Royal Infirmary, Hull, United Kingdom; 8Evangelical Hospital, Vienna, Austria; 9Hospital Clinic de Barcelona, Barcelona, Spain; 10Bristol-Myers Squibb, Rueil-Malmaison, France; 11Excelya, Boulogne-Billancourt, France; 12Bristol-Myers Squibb, Munich, Germany; 13Bristol-Myers Squibb, Princeton, United States of America

Background: ASCORE (Abatacept [ABA] Subcutaneous) is a randomized placebo controlled 2-year trial comparing a subcutaneous formulation of ABA with placebo in patients with RA inadequately controlled on csDMARD plus non-bDMARD therapy

Objectives: To present the first 1-year interim interim median rates and clinical outcomes by previous biologic (b)DMARD exposure.

Methods: Ps (≥ 18 years) with moderate-to-severe RA, who initiated SC ABA 125 mg weekly, were enrolled (Mar 2013–Jan 2017) across 10 countries in two cohorts: biologic-naive pts and those who had failed ≥ 1 prior bDMARD. Pt and disease characteristics were recorded. ABA reactivation rates (95% CI) were estimated at 1 year by Kaplan–Meier analysis.

Conclusion: The safety profile was similar across patient cohorts and consistent with real-world IV ABA studies.1,2

REFERENCES

Acknowledgement: Professional medical writing: Fiona Boswell, PhD, Caudex; funding: Bristol-Myers Squibb

Figure 1

Disclosure of Interests: Rieke Allen Grant/research support from: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, Xavier Mariette Consultant for: Honorarium from Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Janssen, Pfizer, UCB, Maya Buch Grant/research support from: Pfizer LTD, UCB, Consultant for: AbbVie, Eli Lilly, EMD Serono, Pfizer Ltd., Sanofi, Roberto Caporali Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Roche, Genzyme, Lilly, MSD, Pfizer, UCB, Rene-Marc Filipo Consultant for: Advisory board: Bristol-Myers Squibb, Adrian Forster Consultant for: Consultant for Pfizer, MSD, Grünenthal, Novartis and Roche, Michael Nurmmohamed Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB, Yusuf Patel: None declared, Peter Peichl Speakers bureau: Speaker: Eli Lilly, Pfizer, Bristol-Myers Squibb, Raimon Sanmarti Grant/research support from: Research support: Bristol-Myers Squibb, Speakers bureau: Speakers bureau: Bristol-Myers Squibb, Melanie Chartier Employee of: Bristol-Myers Squibb, Julia Heitmann Employee of: Employee of Excelya which received funding from Bristol-Myers Squibb as contract research organization for this study, Christiane Rauch Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Sean Connolly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb


Figure 1

Disclosure of Interests: Rieke Allen Grant/research support from: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, Xavier Mariette Consultant for: Honorarium from Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Janssen, Pfizer, UCB, Maya Buch Grant/research support from: Pfizer LTD, UCB, Consultant for: AbbVie, Eli Lilly, EMD Serono, Pfizer Ltd., Sanofi, Roberto Caporali Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Roche, Genzyme, Lilly, MSD, Pfizer, UCB, Rene-Marc Filipo Consultant for: Advisory board: Bristol-Myers Squibb, Adrian Forster Consultant for: Consultant for Pfizer, MSD, Grünenthal, Novartis and Roche, Michael Nurmmohamed Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi and UCB, Yusuf Patel: None declared, Peter Peichl Speakers bureau: Speaker: Eli Lilly, Pfizer, Bristol-Myers Squibb, Raimon Sanmarti Grant/research support from: Research support: Bristol-Myers Squibb, Speakers bureau: Speakers bureau: Bristol-Myers Squibb, Melanie Chartier Employee of: Bristol-Myers Squibb, Julia Heitmann Employee of: Employee of Excelya which received funding from Bristol-Myers Squibb as contract research organization for this study, Christiane Rauch Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Sean Connolly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb